Fig. 3

a–d: Kaplan–Meier survival curve for DCM patients with the multivariate assessment of the effect of IVIg administration (a), age of presentation (b) EF at presentation (c), and ICU admission (d) on survival. The mortality rate among DCM patients was 30% with most deaths occurring in the first 2 years after the diagnosis. IVIg administration had no significant effect on reducing the mortality (p-value 0.074). EF at the presentation of 20% or less had a significant risk for a bad outcome (p-value < 0.001). Patients admitted to the ICU had a higher mortality rate (p-value 0.047)